Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

被引：12

作者：

Kasi, Pashtoon Murtaza ^{[1
]}

Aushev, Vasily N. ^{[2
]}

Ensor, Joe ^{[2
]}

Langer, Nathan ^{[3
]}

Wang, Christopher Gene ^{[4
]}

Cannon, Timothy Lewis ^{[5
]}

Berim, Lyudmyla Derby ^{[6
]}

Feinstein, Trevor ^{[7
]}

Grothey, Axel ^{[8
]}

McCollom, Joseph William ^{[9
]}

Kalmadi, Sujith R. ^{[10
]}

Zakari, Ahmed ^{[11
]}

Dayyani, Farshid ^{[12
]}

Gravenor, Donald ^{[13
]}

Meyer, Janelle Marie ^{[14
]}

Sharif, Saima ^{[15
]}

Jurdi, Adham A. ^{[2
]}

Liu, Minetta C. ^{[2
]}

Aleshin, Alexey ^{[2
]}

Kopetz, Scott ^{[16
]}

机构：

[1] NewYork Presbyterian Hosp, Englander Inst Precis Med, Weill Cornell Med, New York, NY USA

[2] Natera Inc, Austin, TX USA

[3] Virginia Canc Inst QCCA, Richmond, VA USA

[4] Alabama Oncol, Birmingham, AL USA

[5] Inova Schar Canc Inst, Fairfax, VA USA

[6] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[7] Piedmont Canc Inst, Atlanta, GA USA

[8] West Canc Ctr, Germantown, TN USA

[9] Parkview Canc Inst, Ft Wayne, IN USA

[10] Ironwood Canc & Res Ctr, Chandler, AZ USA

[11] Adventhlth Canc Inst, Orlando, FL USA

[12] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Orange, CA USA

[13] Baptist Canc Ctr, Memphis, TN USA

[14] Oregon Oncol Specialists, Salem, OR USA

[15] Univ Iowa, Iowa City, IA USA

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

283-237-255; 281-206-4760-6705; 261-376-454; 281-318-9508; 281-318-9493; 261-492-3532-2370-7650-2454; 261-376; 9; 7; 6; 4; 2;

D O I：

10.1200/JCO.2024.42.3_suppl.9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：9 / 9

页数：1

共 50 条

[41] A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).
Parikh, Aparna Raj
Van Seventer, Emily E.
Boland, Genevieve Marie
Hartwig, Anna
Jaimovich, Ariel
Raymond, Victoria M.
Talasaz, AmirAli
Corcoran, Ryan Bruce
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[42] Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
Chakrabarti, Sakti
Kasi, Anup Kumar
Parikh, Aparna R.
Mahipal, Amit
CANCERS, 2022, 14 (13)
[43] PLASMA BASED CELL-FREE CIRCULATING TUMOR DNA (CTDNA) ASSESSMENT FOR NON-INVASIVE DETECTION OF COLORECTAL CANCER (CRC)
Dean, Jason
He, Yupeng
Raymond, Victoria
Kim, Seung Tae
Lee, Jeeyun
Kim, Hee Cheol
Jaimovich, Ariel
Talasaz, AmirAli
GASTROENTEROLOGY, 2020, 158 (06) : S369 - S369
[44] Circulating tumor DNA (ctDNA) from patients (pts) with advanced colorectal cancer (CRC) is enriched for EGFR extracellular domain (ECD) mutations
Tejpar, S.
Tukachinsky, H.
Zhang, L.
Schrock, A. B.
Decker, B.
Pavlick, D. C.
Venstrom, J.
Nimeiri, H.
Oxnard, G.
ANNALS OF ONCOLOGY, 2021, 32 : S561 - S561
[45] Analysis of circulating tumour DNA for early relapse detection in stage III colorectal cancer after adjuvant chemotherapy
Jacobs, S. A.
Sethi, H.
Kolveska, T.
George, T. J.
Shchegrova, S.
Tin, T.
Lee, J.
Olson, A.
Renner, D.
Kalashnikova, E.
Yothers, G.
Wolmark, N.
Pogue-Geile, K. L.
Srinivasan, A.
Kortmansky, J.
Louie, M.
Salari, R.
Zimmermann, B.
Aleshin, A.
Allegra, C. J.
ANNALS OF ONCOLOGY, 2019, 30
[46] Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for molecular residual disease (MRD) detection in surgical patients with stage I-IV colorectal cancer (CRC).
Cao, Di
Wang, Fu-Long
Li, Cong
Zhang, Rong-Xin
Wu, Xiao-Jun
Li, Liren
Lu, Zhen-Hai
Pan, Zhi-Zhong
Lin, Jun-zhong
Wu, Miaoqing
Liu, Yifan
Lv, Guangzhao
Li, Min
Wang, Chenyang
Li, Xi
Chen, Gong
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 213 - 213
[47] Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in stage 1-3 colorectal cancer (CRC) in clinical practice
Somer, B.
Mehler, S.
Hasenburg, A.
Greene, H.
Tauer, K.
Grothey, A.
ANNALS OF ONCOLOGY, 2022, 33 : S347 - S347
[48] Genomic alterations in circulating tumor DNA (ctDNA) and response to telisotuzumab adizutecan (ABBV-400) treatment in patients (pts) with colorectal cancer (CRC).
Cecchini, Michael
Sharma, Manish R.
Kuboki, Yasutoshi
Perets, Ruth
Cohen, Jonathan
Raimbourg, Judith
Nakajima, Takako Eguchi
Cruz-Correa, Marcia
Ghiringhelli, Francois
Raghav, Kanwal Pratap Singh
Vasilopoulos, Athanasios
Luo, Xizhi
Aristide, Martha Raluca Neagu
Thiele, Gladys Morrison
Hunter, Zoe
Burns, Michael Charles
Roberts-Rapp, Lisa
Strickler, John H.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 258 - 258
[49] Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC).
Strickler, John H.
Banks, Kimberly C.
Nagy, Rebecca J.
Lanman, Richard B.
Talasaz, AmirAli
Corcoran, Ryan Bruce
Kopetz, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[50] Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.
Morris, Van K.
Yothers, Greg
Kopetz, Scott
Puhalla, Shannon L.
Lucas, Peter C.
Iqbal, Atif
Boland, Patrick M.
Deming, Dustin A.
Scott, Aaron J.
Lim, Howard J.
Jacobs, Samuel A.
Hong, Theodore S.
Wolmark, Norman
George, Thomas J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 5 - 5

← 1 2 3 4 5 →